33
Participants
Start Date
June 30, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
July 31, 2028
Obinutuzumab
"Patient will receive 1000 milligrams intravenous (IV) infusion on week 0, week 2, week 24 and week 26.~Patients will receive the same standardized glucocorticoid tapering schedule (prescribe as a standard of care management and considered as auxiliary medicinal product)~Premedication for obinutuzumab infusion related reactions (considered as auxiliary medicinal products) :~* 100 mg methylpredinisolone~* 1000 mg paracetamol~* 5 mg dexchlorpheniramine"
"Service de Médecine Interne, Centre de reference Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques", Paris
Assistance Publique - Hôpitaux de Paris
OTHER